In April, the home health index was already a little bit lonely.
LHC Group no longer has a stock ticker next to its name now that it’s part of UnitedHealth Group’s (NYSE: UHG) Optum, and thus is no longer a part of the index.
Now, April looks like it could be one of the last months ever in which another legacy home health provider, Amedisys Inc. (Nasdaq: AMED), was a genuine part of the index. In the first week of May, Option Care Health (Nasdaq: OPCH) and Amedisys announced a planned merger that valued the latter at $3.6 billion.
Though Option Care Health and Amedisys shareholders — as well as regulators — still have to approve the deal, the companies expect to close in the back half of 2023.
But if another home health company does exit the public market, it could be representative of an overall trend in the industry at large. The payment landscape — both in traditional Medicare and Medicare Advantage (MA) — is uncertain, which could be a major reason why providers are willing to join forces with deep-pocketed partners.
“There’s undoubtedly labor pressures, but that has always been the case to some extent,” says Ben Bogan, partner and managing director at Stoneridge Partners. “Now, even the largest providers are struggling to navigate an increasingly difficult payment landscape that doesn’t seem to be easing up any time soon.”
The HHI was up 5.82% in April, while the PAI was up 8.45%. It was a good month for both, as the S&P was only up 1.46% during the same period.
Home Health Index
Amedisys was up 9.18% in April. Enhabit Inc. (NYSE: EHAB), on the other hand, was down 11.93%.
Since Enhabit’s IPO last year, the company’s stock price has been cut in half, from $25 per share to $12.25 per share.
At the middle of Enhabit’s woes are MA contracts. Enhabit had started to deny coverage to patients under MA plans that were paying what its leaders considered unfair rates. The company is announcing new deals with MA plans by the quarter, but in the interim, the financials remain rocky.
“To date, we have visited branch operations and sales teams covering 159 branches,” Enhabit CEO Barb Jacobsmeyer said on the company’s first-quarter earnings call. “We believe it’s important to take time to sit down and be transparent as we present not only how, but why, we must deselect certain payers and replace them with the new regional and national agreements.”
Beginning May 1, Enhabit has a new, more favorable deal with an unnamed national MA plan, as well as two unnamed conveners.
Post-Acute Care Index
While Enhabit is working on its payer innovation, it is also working on another key focus area: staffing.
That is precisely what has been holding Aveanna Healthcare Holdings Inc. (Nasdaq: AVAH) – which had its IPO in 2021 – back for the past couple of years.
“As a reminder, we do not have a demand problem,” Aveanna CEO Jeff Shaner said during the company’s first-quarter earnings call. “[Staffing] represents the primary challenge that we are aggressively addressing in 2023, to see Aveanna resume the growth trajectory that we believe our company can achieve.”
Aveanna was up 18.27% in April, but that only represented a 19-cent increase in its stock price. On its first day on the public market in 2021, its stock price was $12 per share.
Aveanna operates more in the Medicaid space, as does Addus Homecare Corporation (Nasdaq: ADUS). Addus was down a whopping 23.44% in April.
That could be due to the Medicaid proposed rule that the Centers for Medicare & Medicaid Services (CMS) recently released, which would mandate that 80% of all payment for home- and community-based services be spent on the workforce.
The proposed rule will likely be altered before it is finalized, but it has caused some concern for providers in the space.
Provider leaders argue that the threshold is nonsensical, mostly because Medicaid programs vary significantly state by state. They also wonder whether training costs will be included in that 80%.
“This proposed rule has a stated goal of improving access to services for Medicaid beneficiaries, which we strongly support,” Addus CEO Dirk Allison said on the company’s first-quarter earnings call. “But while we agree with the goal of broadening coverage, we question the specific approach proposed and the target threshold, as there are inherent challenges at setting a one-size-fits-all minimum percentage.”
Quote of the Month
“There’s still nothing more powerful than exercise for protecting the brain. It can help with depression as well as lowing the risk of many cancers, heart disease, and strokes. The American Heart Association recommends 30 minutes of cardiovascular activity five days a week and a few days a week of strength training.” – Ashtabula County Medical Center Family and Sports Medicine physician, Dr. Nathaniel Franley
Read the Full Article Here: Maintaining Good Mental Health Important for Seniors
See It To Believe It!
The Stoneridge Partners Home Health Index (HH Index) is updated monthly and measures the performance of these two publicly traded home health companies, all listed on the NASDAQ:
*NOTE: LHC Group was officially delisted from the Nasdaq when UnitedHealth Group’s (NYSE: UNH) acquisition of it was finalized. While LHC Group is now gone from the HHI, Enhabit has been added in the past year. The numbers below are reflected as such.
- Amedisys (AMED)
- Enhabit (EHAB)
Here are the results of the stock prices for the past two years:
Company | 4/30/23 | 1 mos change | YTD change | 4/30/22 | 4/30/21 |
Amedisys | 80.30 | +9.18% | -3.88% | 127.65 | 269.85 |
Enhabit | 12.25 | -11.93% | -6.91% | – | – |
HH Index* | 46.28 | +5.82% | -62.26% | 293.50 | 478.12 |
S&P | 4169.48 | +1.46% | +7.53% | 4117.75 | 4181.17 |
Addus | 81.74 | -23.44% | -17.75% | 84.28 | 105.8 |
Although we track the performance of Addus, they are not included in our HH Index because very little of their revenue comes from Medicare.
Enterprise Value (EV)
EV (in M) | 2023 | 2022 | 2021 |
Amedisys | 3120 | 4660 | 9560 |
Enhabit | 1290 | – | – |
HH Index Total | 4410 | 10570 | 15990 |
Addus | 1910 | 1450 | 1780 |
Enterprise Value (EV), aka Selling Price, as Percent of Revenue
Company | 2023 | 2022 | 2021 |
Amedisys | 140% | 210% | 452% |
Enhabit | 119% | – | – |
HH Index Average* | 130% | 238% | 382% |
Addus | 200% | 168% | 232% |
The Stoneridge Partners Post-Acute Care Index is updated monthly and measures the performance of these six publicly traded post-acute care companies, all listed on the NASDAQ:
- Aveanna (AVAH)
- Amedisys (AMED)
- Addus (ADUS)
- The Pennant Group, Inc. (PNTG)
- Encompass Health (EHC)
- Enhabit (EHAB)
- Brookdale Senior Living Inc. (BKD)
This graph displays Post-Acute Care Index performance starting late 2019.
The above calculations are based on selling price being defined as Enterprise Value (EV), with data provided by Capital IQ. Enterprise value is defined as market cap plus debt, minority interest and preferred shares, minus total cash and cash equivalents. EBITDA is calculated using methodology which may differ from that used by a company for its reporting. (Home Health Index May 2023 | Stoneridge Partners)
Recent Transactions From Around The Country
- HouseWorks acquired Care and Help Home Care, a Pennsylvania home care company
SOLD by Stoneridge!!!
- Stoneridge Partners is proud to announce the successful sale of a home health care agency in Colorado
- Stoneridge Partners is proud to announce the successful sale of a therapeutics agency in New York
View Stoneridge closed transactions on our website
Exclusively Listed For Sale By Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
Do you know of any acquisitions that have taken place? We are interested in your comments. Contact us at Stoneridge Partners.
$9M+ in revenue with $1.8M in EBITDA. 4 locations with 30 years in the community. Strong tenured staff conducting over 27,000 appointments annually. CON state...
Hospice. 100+ ADC. Accredited. No CAP or regulatory issues.
$5M in revenue. Located in Northern/Richmond VA. Health system-owned Medicare home health and hospice. Growing organization.
Non-medical Home Care agency. $2M+ in revenue. Medicaid. Profitable.
Non-medical Home Care agency. $3M+ in revenue. Multiple offices.
Hospice. 100+ ADC. Multi-location. No CAP or regulatory issues.
Large multi-discipline pediatric therapy practice. $5+M in revenue. Multiple offices with a wide geographical footprint. Full compliment of management and staff in place.
Medicare-certified home health. Opportunity to establish home health presence in Texas. Minimal census.
$14.9M in revenue with $3M of EBITDA. Second largest residential treatment provider for SUD in KY. Over 350 beds for residential, PHP, IOP, and OP...
$4.1M+ in revenue with $1.7M+ of EBITDA. Community-based outreach program offering mental health services to primarily children and adolescents. High barrier to entry; accreditation required....
$4.5+M Houston-based Medicaid home care company. Established 13 years ago. Excellent HHSC contracts are in place, resulting in an impressive bottom line. Fully staffed.
Non-medical home care franchise. $2M in revenue. 60% private pay. 20% EBITDA. Houston market.
Medicare/Medicaid-certified home health agency. $1.4M in revenue. District 9. Profitable. Accredited.
Behavioral health, therapy, and educational services business. $1.8M in revenue with over $600,000 EBITDA. Services include ABA, early intervention services to children aged 0-21, and...
Home Care Agency. $12M in revenue. 97% Medicaid. Highly profitable agency with strong growth trajectory.
$3.2 million in revenue. JCAHO accredited Home Health company. Showing remarkable growth trends and is very profitable.
Home Health & Hospice with $4.5M in revenue. Medicare/Medicaid certified. Excellent growth potential in large service area.
Hospice with $2.4M+ in revenue. Medicare/Medicaid certified. Full complement of staff in place.
Home care agency. $30M+ in revenue. 95% Medicaid. Platform opportunity.
$3M pediatric agency in Chicago. Long-term management in place.
Medicaid-certified home care. Minimal census. Opportunity to establish home care presence in Texas.
Hospice business. Low census. The license covers all of Clark County (Las Vegas and Henderson)
Non-medical home care franchisee. $9.6+M in revenue. 50% Medicaid/30% Private Pay/ 14% VA/ 6% Misc. Experienced management team to stay post-transition.
$2M revenue home care agency. 100% private pay. Primarily non-medical. Skilled designation, not Medicare-certified. W-2 caregivers. Region 8. Accredited.
Profitable private-duty home health agency in Northern Virginia. $1.5M in revenue. 20+ years in the community.
Profitable home care franchise with consistent sales growth. Revenue of $1.3M. Great reputation within the community.
$40M+ home care agency with 20+% AEBITDA. Primarily private-duty, non-medical (90%). Medicaid waiver programs. 40% family caregivers. Multiple locations.
Home Care / Pennsylvania / Popular
Medicare-certified home health agency. Houston/Kingwood area. Approximately $600k in revenue. Accredited.
Medicare-certified home health agency. District 7. Census of approximately 30 patients. Accredited.
Medicare home health agency. Health system relationship. Rare KY CON opportunity, multiple counties
Home Health / Kentucky / Popular
Home health with $8M in revenue. Medicare/Medicaid-certified. 90+% traditional Medicare/episodic. Services central Texas and licensed for entire state. Strong management team in place.
Home Health / Texas / Popular
Medicare-certified home health agency. Houston-area. Minimal census.
Home Health / Texas / Popular
Medicare-certified home health agency. District 3. Approximately $700k in revenue. Accredited.
Medicare-certified home health agency. District 5. Minimal census. Accredited.
Home Health Index May 2023 | Stoneridge Partners
From Ben Bogan, Publisher of “Home Health Index.” Ben can be reached at [email protected] or (239) 561-0826, and toll-free at 800-218-3944. Previous editions of this monthly newsletter can be searched for at the bottom of the home page of the Home Health Index. Links to Google Finance: Amedisys | LHC Group